Table 1
Characteristics of four different oral formulations
| Tablet | Powder | Suspension | Syrup | |
|---|---|---|---|---|
| Picture |  |  |  |  |
| Appearance | Round biconvex white tablets | Freely flowing powder | Homogeneous and opaque liquid after shaking | Clear solution |
| Dosing recommendation | 1 tablet of 4 mm (43.0 mg) | 250 mg powder (1 sachet) | 2.5 mL | 2.5 mL |
| Taste | Aimed at neutral | Aimed at neutral | Aimed at neutral | Aimed at neutral |
| Dosing device | Not applicable | Not applicable (spoon is an example to show the powder and is not dispensed to the participant) | 3 mL oral syringe with 0.1 mL graduation. The syringe can be attached to the cap of the container | 3 mL oral syringe with 0.1 mL graduation. The syringe can be attached to the cap of the container |
| Composition | Lactose monohydrate 34.69 g Maydis amylum 6.46 g Maydis amylum pregelificatum 1.42 g Magnesium stearate 0.43 g | Lactose monohydrate 203.7 mg Maydis amylum 38.0 mg Maydis amylum pregelificatum 8.3 mg Total 250 mg | Methylparahydroxybenzoate 46.0 mg aluminiummagnesiumsilicate 484.4 mg Carboxymethylcellulose 484.5 mg Citric acid 36.3 mg Sucrose 12.74 g Purified water 37.95 g Microcrystalline cellulosis 2.50 g Purified water ad 50 mL | Methylparahydroxybenzoate 63.1 mg Propylparahydroxybenzoate 10.0 mg Citric acid monohydrate 37.5 mg Saccharose 8.28 g purified water ad 50 mL |